fashion -WSS

fashion

author：leisure time 2025-09-30 23:39:03 - browse：5

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Orchard's therapy for neuron disease in children wins FDA approval

WSS

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

U.K. researchers warn about biases in medical devices, algorithms

Sanofi strikes deal with Novavax, boosting the vaccine maker

Researchers on aging grapple with how to calculate biological age

App could help diagnose ear infections more accurately — and at home

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

knowledge

fashion

leisure time

Guidelines to prevent youth baseball injuries need more muscle

How to improve immunocompromised access to mAb treatments

Hepatitis C has a cure — but many Americans still lack access to it

Future doctors should be trained to promote social change

Walensky prepares to leave CDC — and Congress — behind

Baby aspirin cuts fat buildup in liver disease patients, in small study

Activists slam private health insurers over coverage restrictions

U.K. researchers warn about biases in medical devices, algorithms

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Plastic surgeons increase patient psychiatric screenings

focus

Health AI adoption puts security, privacy startups on investors' radar

Asbestos, a deadly carcinogen, banned by EPA

Future doctors should be trained to promote social change

H5N1 bird flu: what we're starting to learn about infection in cows

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Creating egg and sperm cells from stem cells raises ethical issues

knowledge

entertainment

entertainment

Wikipedia